ITM and Swiss institute to develop therapeutic isotope

2018 12 11 00 02 7009 Atom Nuclear Lab 400

ITM Isotope Technologies Munich and the Paul Scherrer Institute plan to co-develop the radionuclide terbium-161 (Tb-161) for cancer therapy.

The companies will combine their respective technologies and expertise toward developing a large-scale production process for Tb-161, which has shown promise in preliminary studies as a therapeutic radionuclide in prostate cancer.

This collaboration significantly expands ITM's production and development portfolio for medical isotopes in precision oncology, ITM said in a news release.

Page 1 of 543
Next Page